

Redfund Capital Corp.

Consolidated Financial Statements

September 30, 2019

(Expressed in Canadian Dollars)



INDEPENDENT AUDITOR'S REPORT

To the Shareholders of Redfund Capital Corp.

Opinion

We have audited the consolidated financial statements of Redfund Capital Corp. (the "Company"), which comprise the consolidated statements of financial position as at September 30, 2019 and 2018, and the consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at September 30, 2019 and 2018, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 to the financial statements, which indicates that the Company has incurred losses and negative operating cash flows as at September 30, 2019 and the Company's ability to continue its operations is dependent on its ability to raise additional equity financing and to generate operational cash flow. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Other Information

Management is responsible for the other information. The other information comprises the information included in Management's Discussion and Analysis.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
 Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is David Goertz.

DMCL

DALE MATHESON CARR-HILTON LABONTE LLP CHARTERED PROFESSIONAL ACCOUNTANTS

Vancouver, BC

January 28, 2020



Consolidated Statements of Financial Position

		September 30, 2019	September 30, 2018
	Note	\$	\$
Assets			
Current assets			
Cash		18,280	928,249
Interest Receivable		24,276	-
Prepaid		-	164,583
		42,556	1,092,832
Non-current assets			
Convertible loans receivable	4	726,886	-
		726,886	-
Total assets		769,442	1,092,832
Liabilities and shareholders' equity			
Current liabilities			
Accounts payable and accrued liabilities	7	159,655	349,494
Total liabilities		159,655	349,494
Shareholders' equity			
Share capital	5	29,679,528	27,303,591
Reserves	5	6,869,055	6,443,836
Subscriptions received in advance	5	-	564,208
Deficit		(35,938,796)	(33,568,297)
Total shareholders' equity		609,787	743,338
Total liabilities and shareholders' equity		769,442	1,092,832
Nature of operations and going concern	1		
Subsequent event	11		

Approved on behalf of t	he Board of Directors on	January 28, 2020:	
"Meris Kott"	Director	"Eugene Hodgson"	Director

Consolidated Statements of Changes in Shareholders' Equity

For the years ended September 30, 2019 and September 30, 2018

	Number of shares #	Share capital \$		Subscriptions received in advance \$	Deficit \$	Total shareholders' equity \$
October 1, 2017	20,178,885	23,509,240	6,372,363	-	(29,816,081)	65,522
Private placement shares issued	7,779,897	1,312,351	71,473	-	-	1,383,824
Units issued for services	2,933,333	550,000	-	-	-	550,000
Acquisition of Ultra Invest	10,304,000	1,932,000	-	-	-	1,932,000
Subscription received in advance	-	-	-	564,208	-	564,208
Loss and comprehensive loss for the year	-	-	-	-	(3,752,216)	(3,752,216)
September 30, 2018	41,196,115	27,303,591	6,443,836	564,208	(33,568,297)	743,338
October 1, 2018	41,196,115	27,303,591	6,443,836	564,208	(33,568,297)	743,338
Private placement shares issued	5,724,999	1,717,500	-	(564,208)	-	1,153,292
Share issue costs	-	(36,167)	6,700	· -	-	(29,467)
Shares issued for services	4,495,833	694,604	-	-	-	694,604
Share-based payments	-	-	418,519	-	-	418,519
Loss and comprehensive loss for the year	-	-	-	-	(2,370,499)	(2,370,499)
September 30, 2019	51,416,947	29,679,528	6,869,055	-	(35,938,796)	609,787

Consolidated Statements of Loss and Comprehensive Loss

For the years ended September 30, 2019 and 2018

		2019	2018	
	Note	\$	\$	
ncome				
Interest income		112,279		
		112,279		
Expenses		, -		
Bank charges		2,622	1,493	
Consulting	7	1,361,215	290,112	
Investor relations and marketing		285,300	56,595	
Office		38,376	11,258	
Professional fees	7	109,419	147,345	
Public relations		405,403	246,597	
Regulatory and filing		61,502	54,316	
Rent	7	7,194	13,500	
Share-based payments	7	418,519	2,482,000	
Travel		131,372	-	
oss from operating expenses		(2,708,643)	(3,303,216)	
impairment of investment	3	(100,000)		
Impairment of convertible loan receivables	4	(100,080)	(449,000)	
Impairment reversal of convertible loan receivables	4	255,000		
Gain on contract settlement	5	267,062		
Unrealized gain on loan receivable	4	1,146	-	
Foreign exchange gain		15,016		
oss and comprehensive loss for the year		(2,370,499)	(3,752,216)	
Loss per share				
Weighted average number of common shares outstanding	•		.= = =	
- Basic #	6	48,476,316	37,798,785	
- Diluted #	6	48,476,316	37,798,785	
Basic loss per share \$	6	(0.05)	(0.10)	
Diluted loss per share \$	6	(0.05)	(0.10)	

Consolidated Statements of Cash Flows

For the years ended September 30, 2019 and September 30, 2018	For the years	ended September	30, 2019 and	l September 30.	2018
---------------------------------------------------------------	---------------	-----------------	--------------	-----------------	------

		2019	2018
	Note	\$	\$
Operating activities			
Loss and comprehensive loss for the year		(2,370,499)	(3,752,216)
Adjustments for:			
Share-based payments		1,380,185	1,932,000
Interest income		-	-
Impairment of investment		100,000	-
Impairment of convertible loans receivable		100,080	449,000
Units issued for services		-	550,000
Impairment reversal of convertible loan receivables		(255,000)	-
Gain on contract settlement		(267,062)	-
Net change in non-cash working capital items	9	(49,532)	90,173
		(1,361,828)	(731,043)
Financing activities			
Subscriptions received in advance		-	564,208
Proceeds from issuance of common shares		1,153,292	1,458,730
Share issue costs		(29,467)	(3,600)
Issuance of convertible notes receivable		(671,966)	(449,000)
		451,859	1,570,338
Net decrease in cash and cash equivalents		(909,969)	839,295
Cash and cash equivalents, beginning of year		928,249	88,954
Cash and cash equivalents, end of year		18,280	928,249

Supplemental cash flow information

9

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

1. Nature of operations and going concern

Redfund Capital Corp. (the "Company") was incorporated under the Business Corporation Act of Alberta on August 31, 1998 and was continued to British Columbia on January 30, 2006. The Company's shares are publicly traded on the Frankfurt Exchange and Canadian Stock Exchange (the "CSE") under the symbol "LOAN".

On August 2, 2018, the Company completed a change of business and corporate name change to become a merchant bank focused on medical cannabis and hemp in both Canada and the United States. The head office, principal address s and records office of the Company are located at 702 – 595 Howe Street, Vancouver, BC V6C 2F5.

These consolidated financial statements ("financial statements") have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at September 30, 2019, the Company is not able to finance day to day activities through operations and incurs losses. The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds there from. This indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and or private placement of common shares. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its statement of financial position.

2. Significant accounting policies

(a) Basis of presentation

These financial statements have been prepared in accordance with International Financial Reporting Standards and Interpretations (collectively, "IFRS"), as issued by the International Accounting Standards Board ("IASB") and the International Financial Reporting Interpretations Committee ("IFRIC").

These financial statements have been prepared on an historical cost basis, except for financial instruments which are classified as fair value through profit or loss ("FVTPL"). In addition, these financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

All amounts on the financial statements are presented in Canadian dollars which is the functional currency of the Company.

(b) New accounting policy

The Company has adopted new accounting standard IFRS 9 - Financial Instruments, effective for annual periods beginning on or after January 1, 2018. The adoption of IFRS 9 did not result in any changes to the classification, measurement, or carrying amounts of the Company's existing financial instruments on transition date. The new standard brings together the classification and measurement, impairment and hedge accounting phases of the IASB's project to replace IAS 39 - Financial instruments: recognition and measurement. The standard retains but simplifies the mixed measurement model and establishes two primary measurement categories for financial assets: amortized cost and fair value.

The Company continues to classify and measure its financial instruments at fair value through profit or loss with changes in fair value recognized in profit or loss as they arise ("FVTPL") unless restrictive criteria regarding the objective and contractual cash flows of the instrument are met for classifying and measuring at either amortized cost or fair value through other comprehensive income.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(b) New accounting policy (continued)

Cash and cash equivalents and marketable securities continue to be recorded at FVTPL. Accounts payable and accrued liabilities, and accounts payable to related parties are classified and measured as other financial liabilities, initially at FVTPL, and subsequently at amortized cost using the effective interest rate method.

(c) Basis of consolidation

These financial statements include the accounts of the Company and its subsidiaries. The results of each subsidiary will continue to be included in the consolidated financial statements of the Company until the date that the Company's control over the subsidiary ceases. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Entity	Incorporation	Status	Functional Currency
Ultra Invest Canada Inc. ("Ultra Invest")	Canada	Inactive	Canadian
Ona Power Oil & Gas Corp ("Ona")	United States	Inactive	US Dollar

(d) Financial instruments

The Company classifies its financial instruments in the following categories: as FVTPL, financial assets at amortized cost and other financial liabilities. The classification depends on the purpose for which the financial assets or liabilities were acquired. Management determines the classification of financial assets and liabilities at initial recognition.

(i) Non-derivative financial assets and liabilities

Recognition

The Company recognizes financial assets and financial liabilities on the date the Company becomes a party to the contractual provisions of the instruments.

Classification

The Company classifies its financial assets and financial liabilities using the following measurement categories:

- (a) Those to be measured subsequently at fair value (either through other comprehensive income (loss) or through profit or loss); and
- (b) Those to be measured at amortized cost.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(d) Financial instruments (continued)

The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at fair value through profit or loss (an irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in profit or loss or other comprehensive income (loss).

The Company reclassifies financial assets when and only when its business model for managing those assets changes. Financial liabilities are not reclassified.

The Company's investment and convertible receivables are classified as FVTPL. Investments and convertible receivables held in companies with an active market are classified as current assets at fair value. Investments and convertible receivables held in non-public companies without an active market are classified as non-current assets and are valued at fair value. In situations where fair value is indeterminable or impracticable to determine, the shares are recorded at cost. This may occur when non-public company shares are received as payment for asset interests. In such situations cost is determined by reference to the issue price of similar shares issued by the non-public entity for cash, at or near the time of issue of the investment shares, and in similar volumes. When, at future measurement dates fair value is still indeterminable, or impracticable, cost is used as the measure of fair value. When there is evidence of impairment the shares are written-down to expected realizable value.

(ii) Derivative financial assets

Warrants are classified as derivative financial assets and are recorded at FVTPL. Warrants without an active market that are received as attachments to common share units are initially recorded at nominal amounts. At the time of purchase the total unit cost is allocated in full to each common share. Subsequent value is determined at measurement date using a valuation technique, such as the Black-Scholes option pricing model, or when the valuation technique input variables are not reliable, using the intrinsic value, which is equal to the higher of the market value of the underlying security, less the exercise price of the warrant, or zero.

(iii) Other financial liabilities

The Company has the following other financial liabilities: accounts payable and accrued liabilities.

Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Interest expense is recorded to profit or loss.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(e) Foreign currency translation

The functional currency of each entity is measured using the currency of the primary economic environment in which that entity operates. The financial statements are presented in Canadian dollars which is the parent company's functional and presentational currency. The functional currency of Ultra Invest is the Canadian dollar and the functional currency of Ona is the US dollar.

Transactions and balances:

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in profit or loss in the statement of comprehensive loss in the period in which they arise, except where deferred in equity as a qualifying cash flow or net investment hedge. Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income in the statement of comprehensive loss to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive loss. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

Foreign operations:

The financial results and position of foreign operations whose functional currency is different from the Company's presentation currency are translated as follows:

- assets and liabilities are translated at period-end exchange rates prevailing at that reporting date; and
- income and expenses are translated at average exchange rates for the period.

Exchange differences arising on translation of foreign operations are recorded to the Company's foreign currency translation reserve. These differences are recognized in the profit or loss in the period in which the operation is disposed of.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(f) Impairment

(i) Financial assets

The Company assesses all information available, including on a forward-looking basis, the expected credit losses associated with its assets carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. To assess whether there is a significant increase in credit risk, the Company compares the risk of a default occurring on the asset as the reporting date, with the risk of default as at the date of initial recognition, based on all information available, and reasonable and supportive forward-looking information.

(ii) Non-financial assets

Non-financial assets are reviewed quarterly by management for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present the recoverable amount of an asset is evaluated at the CGU level, which is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount of a CGU is the greater of the CGU's fair value less costs to sell and its value in use. An impairment loss is recognized in profit or loss to the extent that the carrying amount exceeds the recoverable amount.

(g) Share capital

Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares, share warrants, options and flow-through shares are classified as equity instruments.

Incremental costs directly attributable to the issue of new shares, warrants or options are recognized as a deduction from equity, net of tax.

Valuation of equity units issued in private placements

The Company has adopted a residual value method with respect to the measurement of shares and warrants issued as private placement units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component.

The fair value of common shares issued in private placements was determined to be the more easily measurable component and are valued at their fair value, as determined by the closing quoted bid price on the announcement date. The balance, if any, is allocated to attached warrants. Any fair value attributed to warrants is recorded to reserves of the issued

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(h) Share-based payment transactions

The Company has a stock option plan that provides for the granting of options to Officers, Directors, related company employees and consultants to acquire shares of the Company. The fair value of the options is measured on grant date and is recognized as an expense with a corresponding increase in contributed surplus as the options vest.

Options granted to employees and others providing similar services are measured on grant date at the fair value of the instruments issued. Fair value is determined using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted. The amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest. Each tranche in an award with graded vesting is considered a separate grant with a different vesting date and fair value. Each grant is accounted for on that basis.

Options granted to non-employees are measured at the fair value of the goods or services received, unless that fair value cannot be estimated reliably, in which case the fair value of the equity instruments issued is used. The value of the goods or services is recorded at the earlier of the vesting date, or the date the goods or services are received.

Over the vesting period, share-based payments are recorded as an operating expense and as contributed surplus. When options are exercised, the consideration received is recorded as share capital and the related share-based payments originally recorded as contributed surplus are transferred to share capital. When an option is cancelled, or expires, the initial recorded value is reversed from reserves and credited to deficit.

(i) Income taxes

Income tax expense is comprised of current and deferred income taxes. Current income tax and deferred income tax are recognized in profit or loss, except to the extent that they relate to items recognized directly in equity or equity investments.

Current income tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.

Deferred income tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred income tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred income tax assets and liabilities are offset if there is a legally enforceable right to offset current income tax liabilities and assets, and they relate to income taxes levied by the same tax authority for the same taxable entity. A deferred income tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred income tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related income tax benefit will be realized.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(j) Loss per share

The Company presents basic and diluted loss per share ("LPS") data for its common shares. Basic LPS is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year, adjusted for own shares held. Diluted LPS is determined by dividing the profit or loss attributable to common shareholders by the weighted average number of common shares outstanding, adjusted for own shares held, and for the effects of all potential dilutive common shares related to outstanding stock options and warrants issued by the Company for the years presented, except if their inclusion proves to be anti-dilutive.

(k) Use of estimates and critical judgments

The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates and judgments. Those areas requiring the use of management estimates and judgments include:

Estimates

- (i) Conversion options or sale agreements, under which the Company may receive shares as payment, require the Company to determine the fair value of the shares and/or warrants received. Many factors can enter this determination, including, if public shares, the number of shares received, the trading value of the shares, and volume of shares, and if non-public shares, the underlying asset value of the shares, or value of the claims under option or sale. This determination is subjective and does not necessarily provide a reliable single measure of the fair value of the shares received.
- (ii) The determination of the fair value of stock options or warrants using stock pricing models requires the input of highly subjective variables, including expected price volatility. Wide fluctuations in the variables could materially affect the fair value estimate; therefore, the existing models do not necessarily provide a reliable single measure of the fair value of the Company's stock options and warrants.
- (iii) The fair value of the convertible loan receivables is determined using a discounted cash flow technique which includes inputs that are not based on observable market data and inputs that are derived from observable market data. Where available, the Corporation seeks comparable interest rates and if unavailable, it uses those considered appropriate for the risk profile of a corporation in the industry.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

2. Significant accounting policies (continued)

(I) Use of estimates and critical judgments (continued)

Judgments

(i) The determination of deferred income tax assets or liabilities requires subjective assumptions regarding future income tax rates and the likelihood of utilizing tax carry-forwards. Changes in these assumptions could materially affect the recorded amounts, and therefore do not necessarily provide certainty as to their recorded values.

(m) Standards issued but not yet effective

Certain pronouncements have been issued by the IASB or IFRIC that are effective for accounting periods beginning on or after January 1, 2019. Many of these updates are not applicable or consequential to the Company and have been excluded from the discussion below.

Effective for annual periods beginning on or after January 1, 2019

New standard IFRS 16 - Leases

IFRS 16, Leases ("IFRS 16") was issued by the IASB on January 13, 2016, and will replace IAS 17, Leases. It is effective for annual periods beginning on or after January 1, 2019, with earlier application permitted. IFRS 16 eliminates the current dual accounting model for lessees, which distinguishes between on-balance sheet finance leases and off-balance sheet operating leases. Instead, IFRS 16 requires a single, on-balance sheet accounting model that is similar to current finance lease accounting. Leases become an on-balance sheet liability that attract interest, together with a new asset.

The Company does not have any leases and has initially assessed that there will be no material reporting changes as a result of adopting the new standard.

• New Interpretation IFRIC 23 - Uncertainty over Income Tax Treatments

On June 7, 2017, the IASB issued IFRIC Interpretation 23 - Uncertainty over Income Tax Treatments. The Interpretation provides guidance on the accounting for current and deferred tax liabilities and assets in circumstances in which there is uncertainty over income tax treatments. The Interpretation is applicable for annual periods beginning on or after January 1, 2019. The Company does not expect the adoption of this new standard to have a material impact on its financial statements.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

3. Acquisitions and investments

Mary's Wellness Ltd. ("MWL")

On March 20, 2019, the Company converted its \$100,000 convertible loan receivable to 5% of the common shares in MWL. The investment in MWL was recorded at cost as the Company does not have significant influence nor control over MWL. At September 30, 2019, due to the inability of the Company to obtain recent financial information of MWL and given the Company did not receive any returns from this investment, the Company has impaired this investment to \$nil, resulting in an impairment loss of \$100,000.

Ultra Invest

On August 2, 2018, the Company issued 10,304,000 common shares to the shareholders of Ultra Invest, to acquire all of the issued and outstanding shares of Ultra Invest, a private company controlled by the Company's CEO, Meris Kott, with a fair value of \$1,932,000 (the "Acquisition"). At the time of the Acquisition, Ultra Invest did not constitute a business as defined under IFRS 3, as it had neither operations nor assets; therefore, the Acquisition is accounted under IFRS 2.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

4. Convertible loans receivable

		С	onvertible debenture	receivable
			Face value Fair	value
Balance, October 1, 2017 Biolog, Inc		\$		
	Loan granted		194,000	194,000
	Impairment		(194,000)	(194,000)
	-		•	-
Biominerales Pharma Corp.				
	Loan granted		255,000	255,000
	Impairment		(255,000)	(255,000)
			-	-
Balance, September 30, 2018		\$	-	-
Biominerales Pharma Corp.				
	Loan granted		250,000	250,000
	Impairment reversal		255,000	255,000
	Fair value adjustments		-	(9,712)
	Interest income received		(79,795)	
	Interest income accrued		73,930	-
			499,135	495,288
RxMM Health Capital Inc.				
	Loan granted		220,740	220,740
	Fair value adjustments		-	10,858
	Interest income received		(8,208)	-
	Interest income accrued		30,142	-
			242,674	231,598
Mary's Wellness				
	Loan granted		100,000	100,000
	Converted to investment (Note 3)		(100,000)	(100,000)
			-	
Winterlife Inc.	La con consente d		100.000	400.000
	Loan granted		100,080	100,080
	Impairment of convertible receivable		(100,080)	(100,080)
Balance, September 30, 2019		\$	- 741,809	726,886

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

4. Convertible loans receivable (continued)

Biolog, Inc.

On August 21, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biolog, Inc. ("Biolog"), a private company incorporated in the State of Utah. The Company has agreed to advance up to USD\$800,000 in tranches. Advances are secured by the assets of Biolog and bear interest at 14%, payable monthly, and the promissory note is due on September 1, 2020. On the Effective Date, the Company advanced \$194,000. The note may be converted into common shares of Biolog at a price equal to a 10% discount to the valuation of Biolog immediately from any financing immediately prior to the date of conversion.

In addition, Biolog issued warrants equivalent to 20% of the amount of the note based upon its valuation as of the Effective Date which is stipulated to be USD\$10,000,000. The option to settle the convertible note and warrants in common shares of Biolog represents an embedded derivative in the form of a call option to the Company. Biolog is a private company and its shares cannot be reliably valued using any market-derived indicators. Accordingly, the derivative asset was initially recognized by the Company at \$nil value. As at September 30, 2019, the fair value of the derivative asset remained the same.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Biolog and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable remains impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets.

Biominerales Pharma Corp.

On August 27, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biominerales Pharma Corp. ("Biopharma"), a private company incorporated under the laws of the Province of Quebec. The Company has agreed to advance up to USD\$196,184. Advances are secured by the assets of Biopharma and bears interest at 14% annually, payable monthly; and the promissory note is due on October 1, 2020. On the Effective Date, the Company advanced \$255,000 under the note. The note may be converted into common shares of Biopharma at a price equal to a 10% discount to the price assigned to the common shares of Biopharma from any financing immediately prior to the date of conversion. The Company is not able to exert significant influence over the operations of Biopharma.

In addition, Biopharma issued 18,684 warrants, exercisable at a price of \$2.10 per warrant, to acquire one Class A common share in the capital of Biopharma for a period of 24 months. The option to settle the convertible note and the stock warrants in Class A common shares of Biopharma represents an embedded derivative in the form of a call option. Biopharma is a private company and its shares cannot be reliably valued using any market-derived indicators. As at September 30, 2018, the Company had not received repayment of such note and management has assessed the high likelihood of collectability. Thus, the entire balance of convertible note receivable had been impaired.

On October 1, 2018, a further \$250,000 was loaned to Biopharma under the same terms as the previously loaned \$255,000. This loan continues to be secured by the borrowers' assets. As at September 30, 2019, Biopharma has made monthly interest payments in accordance with the promissory note totaling \$79,795.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been able to review financial information of Biominerales and has assessed the high likelihood of collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable remains and the previous impairment of \$255,000 has been reversed.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

4. Convertible loans receivable (continued)

RxMM Health Capital Inc.

On October 1, 2018, the Company entered into a US\$500,000 promissory note with RxMM Health ("RxMM"). The loan is secured by a general security agreement on assets of RxMM. The loan bears an interest at 14% compounded monthly and is repayable within 24 months. Furthermore, RxMM granted additional consideration to the Company providing an option to purchase common shares of RxMM equal to 20% of the amount of the loan based on a valuation agreed upon between RxMM and the Company. On October 9, 2018, the Company made a first tranche loan of \$220,740 CDN to RxMM. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been able to review qualitative information of RxMM and has assessed the high likelihood of collectability in respect to the principal portion of the loan. As at September 30, 2019, RxMM has made monthly interest payments in accordance with the promissory note totaling \$8,208.

Mary's Wellness Ltd.

On October 15, 2018, the Company entered into a \$1,000,000 promissory note with Mary's Wellness Ltd. ("MWL"). The loan was secured by a general security agreement on assets of MWL. The loan bore an interest rate of 12.5% per annum compounded monthly and was repayable by November 1, 2020. Furthermore, MWL granted additional consideration to the Company providing an option to purchase common shares of MWL equal to 20% of the amount of the loan based on a valuation agreed upon between MWL and the Company. On October 19, 2018, the Company made a first tranche loan of \$100,000 CDN to MWL. This loan was secured by the borrowers' assets. The entire loan was converted on March 20, 2019 to a 5% equity interest in MWL. (Note 3)

Winterlife Inc.

On November 1, 2018, the Company entered into a USD\$1,000,000 promissory note with Winterlife Inc. ("Winterlife"). The loan is secured by a general security agreement on assets of Winterlife made effective on November 1, 2018. The loan bears an interest rate of 14% per annum compounded monthly and is repayable by November 1, 2020. Furthermore, Winterlife granted additional consideration to the Company providing an option to purchase common shares of Winterlife equal to 20% of the amount of the loan based on a valuation agreed upon between Winterlife and the Company. On November 6, 2018, the Company made a first tranche loan of \$100,080 CDN to Winterlife. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Winterlife and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable has been impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. The Company has received \$nil of total interest since the loan's inception.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

5. Share capital

The authorized share capital of the Company consists of unlimited common shares without par value and unlimited preferred shares without par value. All issued shares are fully paid.

Transactions for the issue of share capital during the year ended September 30, 2019:

The Company issued a total of 4,495,833 shares to consultants on the following dates for consulting services rendered:

- February 19, 2019: 200,000 shares for \$40,000
- April 5, 2019: 1,262,500 shares for \$220,937
- April 24, 2019: 833,333 shares for \$141,667
- May 13, 2019: 1,000,000 shares for \$150,000
- July 8, 2019: 1,000,000 shares for \$125,000
- September 6, 2019: 200,000 shares for \$17,000

The above share issuances were recognized as share-based payments and included in consulting expenses. The Company recognized a gain on contract settlement of \$267,062.

On October 11, 2018, the Company closed a private placement by issuing 5,724,999 units at \$0.30 per unit for gross proceeds of \$1,717,500. Each unit consists of one common share and one warrant entitling the holder to one additional common share for \$0.55 for a period of two years from date of grant. \$564,208 of the subscription proceeds were received during the year ended September 30, 2018. A cash commission of \$29,497 was paid and 21,467 broker warrants were issued, containing the same exercise terms as the private placement warrants. The fair value of the 21,467 broker warrants was estimated at \$6,700.

Transactions for the issue of share capital during the year ended September 30, 2018:

On August 2, 2018, the Company closed a private placement and issued 7,779,894 units at \$0.1875 for total proceeds of \$1,458,730. Each unit consists of one common share and one warrant entitling the holder to one additional common share for \$0.34 for a period of 2 years, subject to the Company having the right to accelerate the expiry date if the shares trade at \$0.47 for a period of 14 consecutive days. On August 2, 2018, the Company issued 2,933,333 units to consultants for services rendered at \$550,000, recognized as share-based payments. The warrants issued contain the same exercise terms as the private placement warrants.

A cash commission of \$74,906 was paid and 399,495 broker warrants were issued, containing the same exercise terms as the private placement warrants. The fair value of the 399,495 broker warrants was estimated at \$71,473, using the Black Scholes Option Pricing Model with the following weighted average assumptions: expected dividend yield - 0%, share price of \$0.22, expected volatility - 201% (based on historical volatility), risk-free interest rate – 2.08%, exercise price of \$0.34 and an expected average life of 2 years.

On August 2, 2018, the Company issued 10,304,000 common shares to the shareholders of Ultra Invest (Note 5) recognized as share-based payments.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

5. Share capital (continued)

Stock options

The Company has adopted a stock option plan whereby the Company may from time to grant to directors, officers, employees and consultants options to purchase common shares of the Company provided that the number of options granted, including all options granted by the Company to date, does not exceed 10% of the Company's common shares issued and outstanding at the time of granting stock options. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company or 30 days following cessation of an optionee conducting investor relations activities' position.

A summary of the status of the Company's stock options as at September 30, 2019 and September 30, 2018, and changes during the years then ended is as follows:

	Year ended September 30, 2019		Year ended September 30, 2018	
	Options #	Weighted average exercise price \$	Options #	Weighted average exercise price \$
Options outstanding, beginning of year	1 350 000	- 0.42		
Granted Options outstanding, end of year	1,350,000 1,350,000	0.43 0.43		
Options exercisable, end of year	1,087,500	0.42		

As at September 30, 2019 the Company has stock options outstanding and exercisable as follows:

Options	Options	Exercise	
outstanding	exercisable	price	Expiry date
#	#	\$	
1,050,000	787,500	0.51	October 12, 2023
300,000	300,000	0.17	September 6, 2024
1,350,000	1,087,500		

The following table summarizes information about the stock options outstanding as at September 30, 2019:

Number o	of Weighted	Weighted
Options	average	average
Outstandir	ng remaining life	exercise price
#	(years)	\$
1,350,000	0 4.24	0.43

On October 12, 2018, the Company granted 1,050,000 options to officers, directors and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.51 per share and expires October 12, 2023. These options vested quarterly over one year. These options had a fair value of \$402,000 using the Black Scholes model with the following assumptions: i) exercise price: \$0.51; ii) share price: \$0.51; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 2.38%.

On September 6, 2019, the Company granted 300,000 options to officers, directors and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.17 per share and expires September 6, 2024. These options had a fair value of \$16,519 using the Black Scholes model with the following assumptions: i) exercise price: \$0.17; ii) share price: \$0.09; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 1.40%.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

5. Share capital (continued)

Warrants

As an incentive to complete private placements, the Company may issue units which include common shares and common share purchase warrants. Using the residual value method, the Company determines whether a value should be allocated to the warrants attached to the units sold in completed private placements.

Finders' warrants may be issued as a private placement share issue cost and are valued using the Black-Scholes option pricing model.

A summary of the status of the Company's warrants as at September 30, 2019 and September 30, 2018, and changes during the years then ended is as follows:

	Year ended ended September 30, 2019		Year ended September 30, 2018	
	Warrants #	Weighted average exercise price	Warrants #	Weighted average exercise price
Warrants outstanding, beginning of year	18,223,832	0.26	7,111,110	0.14
Private placement warrants issued	5,724,999	0.55	11,112,722	0.34
Finders' warrants issued	21,467	0.55	-	-
Warrants outstanding, end of year	23,970,298	0.33	18,223,832	0.26

As at September 30, 2019 the Company had private placement warrants outstanding and exercisable as follows:

Warrants outstanding #	Exercise price \$	Expiry date
3,555,555	0.140	January 8, 2021
3,555,555	0.140	August 16, 2021
11,112,722	0.340	August 2, 2020
5,724,999	0.550	October 12, 2020
21,467	0.55	October 12, 2020
23,970,298		

The following table summarizes information about the warrants outstanding as at September 30, 2019:

Range of prices	Warrants Outstanding	average remaining life	average exercise price
\$	#	(years)	\$
0.14	7,111,110	1.58	0.140
0.34	11,112,722	0.84	0.340
0.55	5,746,466	1.04	0.550
	23,970,298	1.11	0.33

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

Share capital (continued)

Warrants (continued)

On August 2, 2018, the Company issued 7,779,894 warrants as part of the previously disclosed private placement on the same date. In addition, the Company issued 399,495 broker warrants containing the same exercise terms as the private placement warrants (see Issued Share Capital above). The broker warrants had a fair value of \$71,473 using the Black Scholes model with the following assumptions: i) exercise price: \$0.34, ii) share price: \$0.22, iii) term: 2 years, iv) volatility: 201%, v) risk-free rate: 2.08%. The value of these broker warrants was included in reserves for the year ended September 30, 2018.

On September 7, 2017, the Company extended the expiry date for the 3,555,555 warrants issued on January 8, 2016 from January 8, 2018 to January 8, 2021. Management elected not to revalue the stock- based compensation associated with the extension of the warrant terms.

On October 11, 2018, the Company issued 5,724,999 warrants as part of the previously disclosed private placement on the same date. In addition, the Company issued 21,467 broker warrants containing the same exercise terms as the private placement warrants (see Issued Share Capital above). The broker warrants had a fair value of \$6,700 using the Black Scholes model with the following assumptions: i) exercise price: \$0.55; ii) share price: \$0.51; iii) term: 2 years; iv) volatility: 111%; v) risk-free rate: 0.66 %. The value of these broker warrants was included in reserves for the year ended September 30, 2019.

6. Loss per share

The calculation of basic and diluted loss per share for the year ended September 30, 2019 was based on the loss attributable to common shareholders of \$2,370,499 (2018 - \$3,752,216) and a weighted average number of common shares outstanding of 48,476,316 (2018 – 37,798,785).

All options and warrants were excluded from the diluted weighted average number of common shares calculation, as their effect would have been anti-dilutive.

7. Related party payables and transactions

A number of key management personnel and directors hold positions in other entities that result in them having control or significant influence over the financial or operating policies of these entities. There were no loans to management personnel or Directors, or entities over which they have control or significant influence, during the years ended September 30, 2019 and September 30, 2018.

Meris Kott, the Company's President and CEO receives a monthly consulting fee and incentive stock options. All other key management personnel and directors receive no salaries, non-cash benefits (other than incentive stock options), or other remuneration directly from the Company, other than noted below, and there are no employment contracts with them that cannot be terminated without penalty on thirty days notice. Key management personnel and directors participate in the Company's stock option plan.

Stock options were granted during the year ended September 30, 2019 to directors and management which had a fair value on grant date of \$291,892 (2018 – nil).

The Company transacted with the following related parties:

- (a) 1060606 BC Ltd. ("106 BC Ltd.") is a consulting firm over which the CEO of the Company has significant influence and ownership. Charges are for consulting, travel, office rent and administration.
- (b) Kelly McQuiggan was a former CFO. He is a consultant of Invictus Accounting Group LLP a firm in which he has influence. Invictus provided the Company with accounting services and professional fees.
- (h) Ryan Cheung was a former CFO. He is owner of MCPA Services Inc. a firm in which he has significant influence. MCPA provided the Company with accounting services and professional fees.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

7. Related party payables and transactions (continued)

The aggregate value of transactions and outstanding balances with key management personnel and Directors and entities over which they have control or significant influence were as follows:

	Transactions year ended September 30, 2019 \$	Transactions year ended September 30, 2018 \$	Balances outstanding September 30, 2019 \$	Balances outstanding September 30, 2018 \$
106 BC Ltd.	·	·		
- consulting services	325,696	213,925	-	-
- travel	106,400	-	-	-
- rent and administration	7,194	-	-	-
	439,290	213,925	-	_
Amanda de Freitas	40,000	-	40,000	_
Invictus	10,763	-	9,013	_
MCPA	18,950	3,675	-	5,250
	509,003	217,600	49,013	5,250

All related party balances are unsecured and are due within thirty days without interest.

The transactions with the key management personnel and Directors are included in operating expenses as follows:

(a) Consulting and travel expenses

- Includes Meris Kott fee related to consulting, administrative and travel related expenses.

(b) Office rent

- Charged by 106 BC Ltd.

(c) Professional fees

- Includes the accounting services of Company's former CFO's, Ryan Cheung and Kelly McQuiggan, charged to the Company by MCPA and Invictus.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

8. Income taxes

The provision for income tax, both current and deferred, differs from the amount calculated by applying the combined expected federal and provincial rate to profit before taxes. The reasons for these differences are as follows:

A reconciliation of income taxes at statutory rates with the reported taxes is as follows:

		2019		2018
Loss for the year	\$	(2,370,499)	\$	(3,752,000)
Expected income tay (recovery)	¢	(640,000)	c	(1.012.000)
Expected income tax (recovery)	\$	(640,000)	\$	(1,013,000)
Change in statutory, foreign tax, foreign exchange rates and other		748,000		90,000
Permanent differences		77,000		-
Losses expired due to change in business		-		3,214,000
Share issue cost		(8,000)		-
Change in unrecognized deductible temporary differences		(177,000)		(2,291,000)
Total income tax recovery	\$	-	\$	-

As of September 30, 2019, the Corporation has approximately the following tax pools available as a deduction from future income at the prescribed tax rates. These tax pools are subject to confirmation by income tax authorities:

	2019	Expiry Date Range	2018	Expiry Date Range
Temporary Differences				
Share issue costs	24,000	2040 to 2043	-	NA
Allowable capital losses	147,000	No expiry date	-	NA
Non-capital losses available for future periods	2,928,000	2026 to 2039	3,752,000	2026 to 2038

As of September 30, 2019, the Corporation has non-capital losses of \$2,928,000 (2018 - \$3,752,000) available to carry forward to reduce future years' taxable income.

Tax attributes are subject to review, and potential adjustment, by tax authorities.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

9. Supplemental cash flow information

Changes in non-cash operating working capital during the years ended September 30, 2019 and September 30, 2018 were comprised of the following:

	September 30 , September 30,		
	2019	2018	
	\$	\$	
Receivables and prepayments	140,307	(161,951)	
Accounts payable and accrued liabilities	(189,839)	252,124	
Net change	(49,532)	90,173	

During the years ended September 30, 2019 and September 30, 2018 there were no amounts paid on account of interest or income taxes.

10. Financial risk management

Capital management

The Company is a merchant bank and considers items included in shareholders' equity as capital. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of underlying assets. In order to maintain or adjust its capital structure, the Company may issue new shares, purchase shares for cancellation pursuant to normal course issuer bids or make special distributions to shareholders. The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. The Company's capital structure as at September 30, 2019 is comprised of shareholders' equity of \$609,787 (September 30, 2018 - \$743,338).

The Company currently has no source of revenues except for interest received from convertible loans. In order to fund future projects and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. The Company's ability to continue as a going concern on a long-term basis and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation is primarily dependent upon its ability to borrow or raise additional financing from equity markets.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

Financial risk management (continued)

Financial instruments - fair value

The Company's financial instruments consist of cash and cash equivalents, investments, convertible loans receivable, accounts payable and accrued liabilities.

The carrying value of accounts payable and accrued liabilities approximates their fair value because of the short-term nature of these instruments.

Financial instruments measured at fair value on the statements of financial position are summarized into the following fair value hierarchy levels:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
September 30, 2019				
Cash	18,280	-	-	18,280
Convertible loan receivable	-	-	726,886	726,886
	18,280	-	726,886	745,166
September 30, 2018				
Cash	928,249	-	-	928,249
	928,249	-	-	928,249

Within Level 3, the Corporation includes the convertible loans receivable and private company investments. The key assumptions driving the valuation of the private company investments include, but are not limited to, the value at which a recent financing was completed by the investee, significant changes in general market conditions and company specific information. For those investments valued based on general market condition and company specific information, these inputs can be highly judgmental. A +/- 25% change in the fair value of these investments will result in a corresponding +/-\$181,750 (2018 - \$nil) change to the total fair value of the investments. While this illustrates the overall effect of changing the values of the unobservable inputs by a set percentage, the significance of the impact and the range of reasonably possible alternative assumptions may differ significantly between investments, given their different circumstances.

The fair value of the convertible loans receivable, which is not traded in an active market, is determined by discounting the stream of future interest and principal repayments at the rate of interest prevailing the balance sheet date for instruments of similar term and risk, and adding this value to the value of the convertibility feature which is estimated using a Black-Scholes model based on assumptions including risk free interest rate, expected dividend yield, expected volatility and expected remaining life of the convertible loans receivable.

Management estimates that the market interest rate on similar borrowing without the conversion feature was approximately 25% and has used an implied volatility of 87.35% in valuing the convertibility feature. Holding all other variables constant, a fluctuation in interest rates of 1% would have impacted the valuation by approximately \$5,000 while a fluctuation in the implied volatility use of 25% would have impacted the valuation by approximately \$1,000.

The sensitivity analysis is intended to reflect the uncertainty inherent in the valuation of these investments under current market conditions and its results cannot be extrapolated due to non-linear effects that changes in valuation assumptions may have on the fair value of these investments. Furthermore, the analysis does not indicate a probability of such changes occurring and it does not necessarily represent the Corporation's view of expected future changes in the fair value of these investments. Any management actions that may be taken to mitigate the inherent risks are not reflected in this analysis.

Notes to the Consolidated Financial Statements

For the years ended September 30, 2019 and September 30, 2018

10. Financial risk management (continued)

Financial instruments - risk

The Company's financial instruments are exposed to certain financial risks, including credit risk, interest rate risk, market risk, and liquidity risk.

a) Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its bank account. All of its cash is deposited in a bank account held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using a major bank that is a high credit quality financial institution as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments.

b) Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to significant foreign exchange risk.

b) liquidity risk

Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time.

Historically, the Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

11. Subsequent event

On December 23, 2019, the Company received notice that a former terminated consultant has filed a claim in small claims court and the Company feels it has no merit.